Four-Year Follow-Up Data for Genentech's Evrysdi Show Contin

– Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMA –


– Ninety-one percent of children were alive at month 48 –


– More than 95% maintained the ability to swallow - without treatment they would have required feeding support and majority would have died within 2 years –


– Evrysdi is now approved in 99 countries with more than 8,500 patients treated globally –

Related Keywords

South San Francisco , California , United States , London , City Of , United Kingdom , British , Levi Garraway , Giovanni Baranello , Institute Of Child Health Hospital , Genentech , Society For Medicines Research , Research Clinical Care Meeting , Drug Administration , European Medicines Agency , Office Of Orphan Products Development , Roche Group , Toddler Development Third Edition , Global Product Development , British Pharmacological Society , Gross Motor Scale , Bayley Scales , Hammersmith Infant Neurological Examination , Clinical Care Meeting , Ormond Street Institute , Child Health , Great Ormond Street Hospital , Global Product , Orphan Drug Designation , Drug Discovery , Medicines Research , Orphan Products Development , Drug Designation , Muscular Atrophy , Prescribing Information , Important Safety Information ,